US98973P1012 - Common Stock - After market: 0.74 +0.05 (+6.72%)
NASDAQ:TCRT (2/3/2023, 7:10:35 PM)-0.01 (-0.94%)
|GICS Sector||Health Care|
|Earnings (Last)||11-14 2022-11-14/bmo||Earnings (Next)||03-28 2023-03-28/amc|
|Ins Owners||1.38%||Inst Owners||N/A|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Houston, Texas and currently employs 41 full-time employees. The company went IPO on 2004-08-20. The firm is engaged in developing adoptive TCR engineered T-cell therapies (TCR-T), designed to treat multiple solid tumor types in large cancer patient populations. The firm is leveraging its cancer mutation hotspot TCR library and its non-viral Sleeping Beauty genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including KRAS, TP53 and EGFR. Its TCR library consists of ten TCRs targeting six solid tumor indications, including non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers. Using its human neoantigen T cell Receptor (hunTR) discovery engine, it analyzes thousands of single T cells simultaneously using bioinformatics and next generation sequencing. Its pipeline includes Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.
ALAUNOS THERAPEUTICS INC
8030 El Rio Street, Parris Building 34, Navy Yard Plaza
Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR...
HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell...
Good morning! It's time for another dive into the biggest pre-market stock movers with the shares rising and falling on Tuesday!
Alaunos Therapeutics (TCRT) has started off underwritten stock offering, the clinical-stage oncology company told in after-hours on Monday.Price, size and other terms not...
HOUSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell...
Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the...
Here you can normally see the latest stock twits on TCRT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.